DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
The nausea and constipation are the same for everyone. What is actually female-specific is narrower and more important: a birth-control interaction that differs by drug, unplanned pregnancies, and what to do before trying to conceive. Here is that part, sourced — not the generic side-effect list you can find anywhere.
This is the single most consequential female-specific fact, and most articles blur it by lumping all GLP-1s together. They are not the same. Tirzepatide — the molecule in Mounjaro and Zepbound — slows stomach emptying enough that, in the manufacturer’s own studies, it cut the peak blood level of oral-contraceptive hormones by about 55–66% after the first dose. Eli Lilly’s label therefore instructs patients on the pill to switch to a non-oral contraceptive, or add a barrier method, for four weeks after starting and after every dose increase. Semaglutide — Ozempic, Wegovy, Rybelsus — was studied the same way and did not meaningfully reduce contraceptive absorption. So if you are on the pill, the honest advice is drug-specific: on tirzepatide, back it up; on semaglutide, you are fine.
The viral term describes unplanned pregnancies on GLP-1s, and there are two real mechanisms behind it. First, meaningful weight loss can restore ovulation in people whose fertility was suppressed by obesity or PCOS— the drug did not cause fertility, it removed a barrier to it. Second, on tirzepatide specifically, the pill can quietly become less reliable (see above). The takeaway is not that GLP-1s are fertility treatments; it is that if pregnancy would be unwelcome, your contraception has to be reliable from day one, not “probably fine.”
GLP-1s are not safe in pregnancy — animal reproduction studies showed harm and there is not enough human data to consider them safe. Because semaglutide has a long half-life, the guidance is to stop it at least two months before trying to conceive; tirzepatide and the others should also be stopped before conception and are not used while breastfeeding. The UK’s MHRA issued explicit advice to this effect in June 2025. If you are planning a pregnancy, this is a conversation to have with your prescriber well ahead of time, not at the last minute.
Two effects women ask about most: menstrual changes and hair thinning. Both are reported, but the evidence points to weight loss itself as the driver rather than a direct hormonal action of the drug. Rapid weight loss shifts the hormones that regulate cycles (which is why cycles often improve in PCOS) and can trigger telogen effluvium, a temporary shedding that follows any significant metabolic change. Neither is a fixed, dose-related side effect the way nausea is — but both are worth tracking, and hair shedding is reduced by hitting a protein target and not losing faster than needed.
None of the above replaces the standard GLP-1 side effects — nausea, vomiting, constipation, diarrhea, and the rare-but-serious ones — which affect everyone. Women simply make up most of the obesity-treatment population, so the whole side-effect profile lands disproportionately on women. For the full drug-by-drug breakdown, see GLP-1 side effects by drug and symptom.